Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Endometrial Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Neoplasms 4 Head and Neck Neoplasms 3 Breast Neoplasms 3 Rectal Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lung Neoplasms 1 Hemangiosarcoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Adenocarcinoma, Clear Cell 1

Interventions

Oxaliplatin 16 Cetuximab 13 Leucovorin 12 Fluorouracil 12 Bevacizumab 10 pembrolizumab 7 Specimen Handling 7 Nivolumab 7 Magnetic Resonance Spectroscopy 6 Irinotecan 6 Capecitabine 6 encorafenib 4 Pemetrexed 4 Gemcitabine 4 Cisplatin 4 cemiplimab 3 Folfox protocol 3 Early Intervention, Educational 3 Carboplatin 3 Biopsy 3 trifluridine tipiracil drug combination 2 relatlimab 2 pertuzumab 2 palbociclib 2 fludarabine 2 durvalumab 2 dehydroftorafur 2 aldesleukin 2 adagrasib 2 X-Rays 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Colonic Neoplasms × dostarlimab × 90 days × Clear all

NCT06567782 2026-05-22

AZUR-4

GlaxoSmithKline

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡